Fragment hopping approach directed at design of HIV IN-LEDGF/p75 interaction inhibitors

References

• Le Douce V, Janossy A, Hallay H, Ali S, Riclet R, Rohr O et al. Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother 2012;67:1063–1074.
   PubMed Web of Science ®Google Scholar
• Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010;85:25–33.
   PubMed Web of Science ®Google Scholar
• Sechi M, Rizzi G, Bacchi A, Carcelli M, Rogolino D, Pala N et al. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors. Bioorg Med Chem 2009;17:2925–2935.
   PubMed Web of Science ®Google Scholar
• Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH et al. An essential role for LEDGF/p75 in HIV integration. Science 2006;314:461–464.
   PubMed Web of Science ®Google Scholar
• Hombrouck A, De Rijck J, Hendrix J, Vandekerckhove L, Voet A, De Maeyer M et al. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog 2007;3:e47.
   PubMed Web of Science ®Google Scholar
• Llano M, Morrison J, Poeschla EM. Virological and cellular roles of the transcriptional coactivator LEDGF/p75. Curr Top Microbiol Immunol 2009;339:125–146.
   PubMedGoogle Scholar
• Al-Mawsawi LQ, Neamati N. Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. Trends Pharmacol Sci 2007;28:526–535.
   PubMed Web of Science ®Google Scholar
• Craigie R. Targeting HIV-1 DNA integration by swapping tethers. Proc Natl Acad Sci USA 2010;107:2735–2736.
   PubMedGoogle Scholar
• Busschots K, Voet A, De Maeyer M, Rain JC, Emiliani S, Benarous R et al. Identification of the LEDGF/p75 binding site in HIV-1 integrase. J Mol Biol 2007;365:1480–1492.
   PubMed Web of Science ®Google Scholar
• Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W et al. Novel targets for HIV therapy. Antiviral Res 2008;80:251–265.
   PubMedGoogle Scholar
• Cherepanov P, Sun ZY, Rahman S, Maertens G, Wagner G, Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol 2005;12:526–532.
   PubMed Web of Science ®Google Scholar
• Al-Mawsawi LQ, Neamati N. Allosteric inhibitor development targeting HIV-1 integrase. ChemMedChem 2011;6:228–241.
   PubMedGoogle Scholar
• Hayouka Z, Hurevich M, Levin A, Benyamini H, Iosub A, Maes M et al. Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. Bioorg Med Chem 2010;18:8388–8395.
   PubMed Web of Science ®Google Scholar
• Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ et al. Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. Biochem Biophys Res Commun 2010;394:260–265.
   PubMedGoogle Scholar
• Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010;6:442–448.
   PubMed Web of Science ®Google Scholar
• De Luca L, Barreca ML, Ferro S, Christ F, Iraci N, Gitto R et al. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 2009;4:1311–1316.
   PubMed Web of Science ®Google Scholar
• De Luca L, Gitto R, Christ F, Ferro S, De Grazia S, Morreale F et al. 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. Antiviral Res 2011;92:102–107.
   PubMed Web of Science ®Google Scholar
• De Luca L, Ferro S, Gitto R, Barreca ML, Agnello S, Christ F et al. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem 2010;18:7515–7521.
   PubMed Web of Science ®Google Scholar
• Accelrys. Catalyst. San Diego, CA: Accelrys, Inc. Available at: http://www.accelrys.com.
   Google Scholar
• Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–748.
   PubMed Web of Science ®Google Scholar
• Barreca ML, Rao A, De Luca L, Zappalà M, Gurnari C, Monforte P et al. Efficient 3D database screening for novel HIV-1 IN inhibitors. J Chem Inf Comput Sci 2004;44:1450–1455.
   PubMedGoogle Scholar
• Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N. Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis. FEBS Lett 2008;582:1425–1430.
   PubMed Web of Science ®Google Scholar
• De Luca L, Ferro S, Morreale F, Chimirri A. Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: a promising approach in anti-retroviral therapy. Mini Rev Med Chem 2011;11:714–727.
   PubMed Web of Science ®Google Scholar
• De Luca L, Ferro S, Morreale F, De Grazia S, Chimirri A. Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75. ChemMedChem 2011;6:1184–1191.
   PubMedGoogle Scholar
• Rao A, Chimirri A, Ferro S, Monforte AM, Monforte P, Zappalà M. Microwave-assisted synthesis of benzimidazole and thiazolidinone derivatives as HIV-1 RT inhibitors. Arkivoc 2004;part(v):147–155.
   Google Scholar
• Ferro S, De Luca L, Barreca ML, De Grazia S, Christ F, Debyser Z et al. New chloro, fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action. Bioorg Med Chem 2010;18:5510–5518.
   PubMed Web of Science ®Google Scholar